Please login to the form below

Not currently logged in
Email:
Password:

NSCLC

This page shows the latest NSCLC news and features for those working in and with pharma, biotech and healthcare.

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

It is estimated that over 34, 000 people in England are diagnosed with NSCLC each year, with roughly 20% of these patients receiving a diagnosis at stage 3. ... There are treatment options available for those diagnosed with stage 3 NSCLC, however if a

Latest news

More from news
Approximately 146 fully matching, plus 412 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...